Key Points
- Insider sale: uniQure insider Walid Abi-Saab sold 1,434 shares on June 26 at an average price of $46.86, totaling about $67,197. After the sale, he still held 168,235 shares.
- Stock and financial snapshot: QURE opened at $46.06 and is up sharply from its 50-day average of $29.02. The company reported a narrower-than-expected quarterly loss, though revenue came in below estimates.
- Wall Street sentiment improved: Several analysts raised price targets recently, including Leerink Partners to $70 and Barclays to $65. The stock currently carries a consensus rating of Moderate Buy with an average target of $64.17.
uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Walid Abi-Saab sold 1,434 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $46.86, for a total value of $67,197.24. Following the transaction, the insider owned 168,235 shares of the company's stock, valued at approximately $7,883,492.10. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Walid Abi-Saab also recently made the following trade(s):
- On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00.
uniQure Stock Down 2.8%
Shares of NASDAQ:QURE opened at $46.06 on Wednesday. The firm has a market cap of $2.91 billion, a PE ratio of -13.24 and a beta of 0.98. The company has a fifty day simple moving average of $29.02 and a 200 day simple moving average of $23.40. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50.
uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, equities research analysts anticipate that uniQure N.V. will post -3.65 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on QURE. Leerink Partners increased their price target on shares of uniQure from $36.00 to $70.00 and gave the stock an "outperform" rating in a research report on Thursday, June 18th. Chardan Capital boosted their price objective on uniQure from $31.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, April 30th. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, March 28th. Barclays raised uniQure from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $25.00 to $65.00 in a report on Thursday, June 18th. Finally, The Goldman Sachs Group lifted their target price on uniQure from $14.00 to $46.00 and gave the stock a "neutral" rating in a research report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, uniQure presently has an average rating of "Moderate Buy" and a consensus price target of $64.17.
View Our Latest Report on uniQure
Institutional Investors Weigh In On uniQure
Several institutional investors and hedge funds have recently bought and sold shares of QURE. State Street Corp lifted its holdings in uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company's stock worth $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company's stock valued at $70,226,000 after purchasing an additional 1,785,275 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company's stock valued at $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. Orbimed Advisors LLC raised its position in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company's stock worth $34,926,000 after purchasing an additional 1,398,749 shares during the period. Finally, MPM Bioimpact LLC acquired a new stake in shares of uniQure during the 4th quarter worth approximately $33,062,000. Institutional investors and hedge funds own 78.83% of the company's stock.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
